OncLive On Air August 2024

In case you missed any, below is a recap of every episode of OncLive On Air® that aired in August 2024. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

In this exclusive episode, Aaron Lisberg, MD, of the University of California, Los Angeles School of Medicine, highlighted key findings from the phase 3 TROPION-Lung01 trial (NCT04656652) investigating how datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with previously treated advanced or metastatic non–small cell lung cancer performed in the population of patients with nonsquamous disease, and the future implications of these findings.

“It will be important to see the final overall survival [OS] analysis,” Lisberg said of the trial. “Once we have all the data, [including] the progression-free survival [PFS] and safety data in the nonsquamous population, in addition to the OS data, we will be able to identify where this therapy lies. But with what we have thus far, [Dato-DXd] is looking encouraging as an alternate to docetaxel in our nonsquamous patients.”

Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC

In this episode, Balazs Halmos, MD, MS, of the Albert Einstein College of Medicine and Montefiore Einstein Comprehensive Cancer Center in Bronx, New York, talked through adverse effects (AEs) associated with the antibody-drug conjugates (ADCs) that are used in non–small cell lung cancer (NSCLC); the safety profile of Dato-DXd, as reported in the TROPION-Lung01 trial in patients with advanced or metastatic NSCLC; and ways to manage these toxicities.

“It’s important for all of us to learn how to treat patients optimally with these ADCs, as they will be part of our treatment armamentarium for likely a long time,” Halmos emphasized.

Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

In this episode, Julia Rotow, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts, highlighted findings from the phase 3 LAURA trial (NCT03521154) investigating osimertinib (Tagrisso) after chemoradiotherapy in patients with stage III EGFR-mutated NSCLC, as well as the analysis of the intracranial activity of Dato-DXd in patients with advanced or metastatic NSCLC in the phase 2 TROPION-Lung05 trial (NCT04484142).

“The tumor-blood-brain barrier is a disruptive blood-brain barrier, and it appears to be allowing some of these larger compounds, like ADCs, to cross it and allow for central nervous system activity that I don’t know if we were previously entirely sure we would see,” Rotow emphasized.

ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

In this episode of OncLive On Air’s partnership with Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis and Karine Tawagi, MD, of the University of Illinois in Chicago, discussed findings from the phase 3 NADINA trial (NCT04949113) investigating neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) compared with adjuvant nivolumab in patients with macroscopic, resectable, stage III melanoma. 

“Experts are saying this is the new standard of care [SOC] for stage III melanoma with positive lymph nodes that have resectable disease,” Tawagi said. “It does establish some important benchmarks, including that it’s the first phase 3 trial in stage III melanoma to evaluate neoadjuvant immunotherapy against adjuvant therapy, which was the prior SOC.”

“When we’re adding more immunotherapies, we are adding the possibility of more toxicities, so we need to be cognizant of that when we’re building the trials and then when we’re implementing this [therapy] in the real world,” Armstrong reminded listeners.

FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

On June 14, 2024, the FDA approved durvalumab (Imfinzi) plus carboplatin and paclitaxel followed by single-agent durvalumab for the treatment of adult patients with primary advanced or recurrent mismatch repair–deficient (dMMR) endometrial cancer. This regulatory decision was supported by data from the phase 3 DUO-E trial (NCT04269200), in which the median PFS was not reached (NR; 95% CI, NR-NR) for patients with dMMR tumors who received the durvalumab regimen (n = 46) vs 7 months (95% CI, 6.7-14.8) for patients who received placebo plus chemotherapy (n = 49; HR, 0.42; 95% CI, 0.22-0.80).

In this exclusive episode, Shannon N. Westin, MD, MPH, FACOG, of The University of Texas MD Anderson Cancer Center in Houston, highlighted this approval’s significance, findings from DUO-E, and potential future directions for this combination in the treatment of patients with endometrial cancer.

“Utilizing a strategy that’s targeted based on the patients’ tumors will hopefully allow for more cures of our patients,” Westin emphasized.

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

In this episode, Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, shared findings from a post hoc analysis of the phase 3 COMMANDS trial (NCT03682536) investigating the correlation between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk myelodysplastic syndromes (MDS) who received luspatercept-aamt (Reblozyl) or epoetin alfa; real-world dose-escalation outcomes in patients with lower-risk MDS who received luspatercept; and multilineage and safety findings from COMMANDS.

“We’re seeing a lot of progress all of a sudden,” Garcia-Manero summarized. “A lot of it is coming in low-risk MDS but I’m seeing some improvement in high-risk disease as well.”

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

In this exclusive episode, Komal Jhaveri, MD, FACP, of Memorial Sloan Kettering Cancer Center in New York, New York, explained the findings and implications of the phase 3 INAVO120 trial (NCT04191499) examining inavolisib (GDC-0077) plus palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer.

“For patients who are recurring on or within 12 months of endocrine therapy, the endocrine-resistant patient population, we will need to remember to obtain their biomarker status,” Jhaveri said. “Determining the biomarker status will be key so these patients could be offered the benefit of the triplet regimen as a first-line metastatic option.”

FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer

On August 1, 2024, the FDA expanded the indication for dostarlimab-gxly (Jemperli) in combination with carboplatin and paclitaxel followed by dostarlimab maintenance therapy to include all patients with primary advanced or recurrent endometrial cancer. This regulatory decision was supported by data from part 1 of the phase 2 RUBY trial (NCT03981796). In RUBY, all-comers who received dostarlimab plus chemotherapy (n = 245) achieved a median OS of 44.6 months (95% CI, 32.6-NR) compared with 28.2 months (95% CI, 22.1-35.6%) among those in the placebo plus chemotherapy arm (n = 249; HR, 0.69; 95% CI, 0.54-0.89; P = .002).

In this episode, Krishnansu S. Tewari, MD, of the University of California Irvine School of Medicine, highlighted the significance of this approval, key findings from RUBY, and the next steps for evaluating dostarlimab in endometrial cancer.

“[RUBY was a] fantastic study, probably the most important clinical trial we’ve had in endometrial cancer,” Tewari emphasized.

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

In this exclusive episode, Anne Chiang, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, explained how lurbinectedin (Zepzelca) has performed in the second-line small cell lung cancer (SCLC) setting, tips for managing the AEs associated with this agent, and how lurbinectedin fits into the SCLC treatment paradigm.

“[Lurbinectedin is] easy to use…a lot of patients have a nice response, and that seems to last for a while, so [this drug] is a go-to, and we hope that will continue,” Chiang said.